Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free CLVR Stock Alerts

Clever Leaves (CLVR) Competitors

Clever Leaves logo
$0.0002 0.00 (0.00%)
As of 06/12/2026 01:56 PM Eastern
Compare

CLVR vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Clever Leaves stock or one of its competitors? MarketBeat compares Clever Leaves with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Clever Leaves include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Clever Leaves compare to Ainos?

Ainos (NASDAQ:AIMDW) and Clever Leaves (NASDAQ:CLVR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Company Net Margins Return on Equity Return on Assets
AinosN/A N/A N/A
Clever Leaves N/A N/A N/A

In the previous week, Ainos had 2 more articles in the media than Clever Leaves. MarketBeat recorded 2 mentions for Ainos and 0 mentions for Clever Leaves. Ainos' average media sentiment score of 0.93 beat Clever Leaves' score of 0.00 indicating that Ainos is being referred to more favorably in the media.

Company Overall Sentiment
Ainos Positive
Clever Leaves Neutral

Ainos has higher earnings, but lower revenue than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ainos$18.11KN/AN/AN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Clever Leaves beats Ainos on 3 of the 5 factors compared between the two stocks.

How does Clever Leaves compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Clever Leaves (NASDAQ:CLVR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Alvotech has higher revenue and earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$559.42MN/AN/AN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Clever Leaves N/A N/A N/A

In the previous week, Alvotech had 1 more articles in the media than Clever Leaves. MarketBeat recorded 1 mentions for Alvotech and 0 mentions for Clever Leaves. Alvotech's average media sentiment score of 1.89 beat Clever Leaves' score of 0.00 indicating that Alvotech is being referred to more favorably in the media.

Company Overall Sentiment
Alvotech Very Positive
Clever Leaves Neutral

Summary

Alvotech beats Clever Leaves on 3 of the 5 factors compared between the two stocks.

How does Clever Leaves compare to Aravive?

Clever Leaves (NASDAQ:CLVR) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Aravive N/A N/A N/A

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Aravive Neutral

6.9% of Clever Leaves shares are owned by institutional investors. Comparatively, 35.8% of Aravive shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Comparatively, 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aravive has lower revenue, but higher earnings than Clever Leaves. Aravive is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A
AraviveN/AN/AN/A-$0.90N/A

Summary

Aravive beats Clever Leaves on 3 of the 5 factors compared between the two stocks.

How does Clever Leaves compare to Atlantic Coastal Acquisition Corp. II?

Clever Leaves (NASDAQ:CLVR) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Atlantic Coastal Acquisition Corp. II N/A N/A N/A

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Atlantic Coastal Acquisition Corp. II'saverage media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Atlantic Coastal Acquisition Corp. II Neutral

Atlantic Coastal Acquisition Corp. II has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A

Summary

Clever Leaves beats Atlantic Coastal Acquisition Corp. II on 3 of the 3 factors compared between the two stocks.

How does Clever Leaves compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Clever Leaves (NASDAQ:CLVR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Clever Leaves N/A N/A N/A

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Biofrontera had 1 more articles in the media than Clever Leaves. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for Clever Leaves. Biofrontera's average media sentiment score of 1.87 beat Clever Leaves' score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Very Positive
Clever Leaves Neutral

Biofrontera has higher revenue and earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

Summary

Biofrontera beats Clever Leaves on 3 of the 5 factors compared between the two stocks.

Get Clever Leaves News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLVR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLVR vs. The Competition

Export
MetricClever LeavesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market CapN/A$936.76M$6.49B$12.31B
Dividend YieldN/A4.84%2.67%5.66%
P/E Ratio0.001.4524.0524.76
Price / Sales0.00129.85542.61168.32
Price / CashN/A20.0627.4837.92
Price / Book0.007.9810.696.90
Net Income-$17.90M-$4.88M$3.57B$337.45M
7 Day PerformanceN/A5.66%1.56%2.84%
1 Month PerformanceN/A5.57%2.49%4.78%
1 Year PerformanceN/A46.87%26.51%33.08%

Clever Leaves Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLVR
Clever Leaves
N/A$0.00
flat		N/A-50.0%$0.00$17.42MN/A560
AIMDW
Ainos
N/A$0.13
-4.7%		N/A+25.5%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.23
+39.0%		N/A-83.2%$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/A-87.6%$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CLVR) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel